Sunday 18 October 2026 Export ARCT’s income statement to Excel — free account

Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $82.0 million, down 46.1% from fiscal 2024. In the quarter to June 2026, revenue fell 89.5%, EPS fell 147.1% and free cash flow fell 245.7%, each against the same quarter a year earlier.

10.34 0.93 −8.25%

Follow ARCT

Alert me

Market cap: $320.3M
P/E: 0.0×
Fwd P/E: −1.9×
Dividend yield: —
F-score: 2/9
Altman Z: −0.61
Beneish M: −1.29
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 8.35%

Capital & Financial Ratios $m

Market Cap 320.32

Revenue 29.37

Net Income (93.28)

Free Cash Flow (72.77)

Net Debt (191.48)

Current Ratio 5.88

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.92)

P/S ratio 10.01

P/B ratio 1.71

Past 5Y EPS Growth —

This Y EPS Growth (42.71%)

Next Y EPS Growth (8.55%)

Next Y revenue growth (77.28%)

Next 5Y EPS Growth (13.65%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 69.33%

10-year low 10-year high

P/B against its own 10 years 28.16%

10-year low 10-year high

EV/Sales against its own 10 years 69.80%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	347	292	231	191
Receivables	32	4	6	2
Inventory	—	—	—	—
Other	—	—	—	—
	387	306	241	197

	2023	2024	2025	Q'26
Payables	5	7	4	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	82	65	36	34

Compound Annual Growth %

	10y	5y	3y
Sales	—	53.78%	(26.43%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	11.93%	(11.61%)	(7.49%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	2	3	—	—	—
’25	29	28	17	7	82
’24	38	50	42	23	152
’23	80	11	45	31	167
’22	5	27	13	160	206
’21	2	2	2	6	12
’20	3	2	2	2	10

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(19)	(20)	—	—	—
’25	(35)	(6)	(17)	(16)	(74)
’24	(6)	(30)	(24)	0	(60)
’23	(36)	51	(32)	(1)	(18)
’22	(49)	(37)	(42)	160	32
’21	(43)	(33)	(17)	(42)	(135)
’20	(12)	(8)	(16)	(7)	(43)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(19)	(20)	—	—	—
’25	(35)	(6)	(17)	(16)	(75)
’24	(6)	(30)	(24)	0	(60)
’23	(37)	50	(33)	(2)	(21)
’22	(51)	(36)	(45)	156	24
’21	(43)	(33)	(18)	(44)	(138)
’20	(12)	(9)	(16)	(7)	(45)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.95)	(0.84)	—	—	—
’25	(0.52)	(0.34)	(0.49)	(1.03)	(2.40)
’24	(1.00)	(0.64)	(0.26)	(1.11)	(3.00)
’23	1.87	(1.98)	(0.61)	(0.40)	(1.00)
’22	(1.94)	(0.82)	(1.33)	4.33	0.35
’21	(2.15)	(2.07)	(2.05)	(1.47)	(7.74)
’20	(0.67)	(0.55)	(0.92)	(1.25)	(3.55)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	12.39	5.81	4.11	4.26	8.51	24.87	11.70	14.21	14.30	5.85	Analyst estimates 2026–2028 Powerpack
	High	45.50	18.06	10.45	15.50	129.71	89.18	40.00	37.75	45.00	24.17
People
People	Employees	19	60	72	88	118	177	170	180	176	111
	Revenue/emp, $m	1.07	0.22	0.22	0.24	0.08	0.07	1.21	0.93	0.87	0.74
Income, $m
Income, $m	Revenue	20	13	16	21	10	12	206	167	152	82
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(2)	(11)	(22)	(26)	(72)	(204)	11	(28)	(81)	(66)
	EBT margin, %	(7.54)	(83.87)	(138.29)	(125.02)	(756.35)	(1,647.98)	5.17	(16.72)	(53.14)	(80.19)
	Net income	(2)	(11)	(22)	(26)	(72)	(204)	9	(30)	(81)	(66)
	Depreciation	0	0	1	1	1	1	2	3	4	3
Per share, $
Per share, $	Revenue	10.03	4.21	1.56	1.72	0.47	0.47	7.79	6.26	5.64	3.00
	Earnings	(0.77)	(3.53)	(2.16)	(2.15)	(3.55)	(7.74)	0.35	(1.00)	(3.00)	(2.40)
	Cash flow	(1.41)	(0.15)	(2.06)	(0.53)	(2.11)	(5.13)	1.21	(0.68)	(2.21)	(2.71)
	Capex	(0.34)	(0.07)	(0.15)	(0.07)	(0.09)	(0.13)	(0.29)	(0.11)	(0.02)	(0.01)
	Free cash flow	(1.75)	(0.22)	(2.21)	(0.60)	(2.20)	(5.26)	0.92	(0.79)	(2.24)	(2.72)
	Book value	0.78	10.95	1.35	2.14	19.53	8.67	10.22	10.46	8.93	7.81
	Shares, m	2	3	10	12	20	26	26	27	27	27
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	49.12	0.00	0.00	0.00
	P/S	0.00	0.00	2.90	6.31	92.34	78.81	2.14	5.28	3.01	2.05
	P/B	19.93	0.73	3.34	5.09	2.22	4.27	1.63	3.16	1.90	0.78
	EV/Sales	0.00	0.00	1.20	3.61	45.40	53.94	0.68	3.69	1.62	0.15
	EV/FCF	(6.54)	35.10	(0.85)	(10.32)	(9.71)	(4.81)	5.79	(29.27)	(4.09)	(0.17)
Cash, $m
Cash, $m	Operating cash flow	(3)	0	(21)	(6)	(43)	(135)	32	(18)	(60)	(74)
	Capex	(1)	0	(1)	(1)	(2)	(3)	(8)	(3)	(1)	0
	Free cash flow	(4)	(1)	(22)	(7)	(45)	(138)	24	(21)	(60)	(75)
Balance, $m
Balance, $m	Working capital	4	40	29	53	418	279	276	305	240	205
	Total debt	0	—	10	16	15	63	61	—	—	—
	Net debt	(8)	(49)	(27)	(56)	(448)	(307)	(331)	(347)	(292)	(231)
	Shareholders’ equity	2	34	14	26	397	228	270	279	241	214
Returns, %
Returns, %	ROA	(3.68)	(33.16)	(45.28)	(41.14)	(25.83)	(46.86)	2.22	(6.76)	(20.93)	(21.39)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(4.43)	(61.64)	(91.85)	(131.82)	(34.17)	(65.20)	3.75	(10.83)	(31.16)	(28.92)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
OBIO Orchestra BioMed Holdings, Inc.	$345.0M	— (loss-making)	— (loss-making)	−89.47% (below 0%: shrinking)	n/m	−25.87% (below 0%: shrinking)	71.59%	(25,404.55%)	Compare
CCCC C4 Therapeutics, Inc.	$342.0M	— (loss-making)	— (loss-making)	+2.75% (above 0%: growing)	n/m	+86.84% (above 0%: growing)	100.00%	(397.88%)	Compare
RLMD Relmada Therapeutics, Inc.	$341.3M	— (loss-making)	—	—	n/m	−50.06% (below 0%: shrinking)	0.00%	0.00%	Compare
IRD Opus Genetics, Inc.	$336.9M	— (loss-making)	— (loss-making)	−73.80% (below 0%: shrinking)	n/m	−16.37% (below 0%: shrinking)	100.00%	(2,182.78%)	Compare
ENTA Enanta Pharmaceuticals, Inc.	$334.1M	— (loss-making)	— (loss-making)	−21.60% (below 0%: shrinking)	n/m	−157.51% (below 0%: shrinking)	100.00%	(120.04%)	Compare
CYPH Cypherpunk Technologies Inc.	$325.5M	4.4×	— (loss-making)	0.00%	n/m	+15.53% (above 0%: growing)	0.00%	0.00%	Compare
ARCT Arcturus Therapeutics Holdings Inc.	$320.3M	— (loss-making)	— (loss-making)	−89.54% (below 0%: shrinking)	n/m	−245.65% (below 0%: shrinking)	100.00%	(863.30%)
AGEN Agenus Inc.	$301.7M	2.3×	4.1×	+34.36% (above 0%: growing)	n/m	−55.25% (below 0%: shrinking)	100.00%	32.72%	Compare
CTNM Contineum Therapeutics, Inc.	$297.2M	— (loss-making)	—	—	n/m	+26.73% (above 0%: growing)	100.00%	0.00%	Compare
Median of peers	$335.5M	—	—	−10.80%	—	−21.12%	100.00%	(60.02%)

All 614 Biotechnology stocks →

Arcturus Therapeutics Holdings Inc. (ARCT) key facts

Concern: Arcturus Therapeutics Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $82.0 million, down 46.1% from fiscal 2024.
Arcturus Therapeutics Holdings Inc. (ARCT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ARCT traded at $10.34, a market capitalization of $320.3 million.
Return on equity was −28.9% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −0.61 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.